Amgen Announces Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric …

… occurring more frequently than placebo) were: nasopharyngitis, upper respiratory tract infection, influenza, back pain, and injection site reactions.
Source: back pain